New Leadership Team Set to Drive Growth and Innovation in Precision Medicine
MedGenome, a leader in multiomics and precision medicine, has announced the appointment of Felix Olale, M.D., Ph.D., as President and Chief Executive Officer, and Jennifer Rose as Executive Vice President and Chief Commercial Officer to spearhead its U.S. operations. This new leadership duo aims to propel MedGenome’s expansion in North America, focusing on delivering groundbreaking insights into disease mechanisms, biomarkers, and personalized medicine through innovative multiomics solutions.
Dr. Olale is a distinguished figure in genomics and healthcare, previously serving as Global Co-Lead of Healthcare Investments at LeapFrog Investments. His expertise in scaling purpose-driven businesses will be instrumental in transforming MedGenome into a preferred partner for academic institutions and biopharma companies, leveraging advanced multiomic and genomic technologies to address significant scientific challenges and develop targeted medicines for patients with unmet needs.
“MedGenome is at the forefront of innovation, partnering with researchers and biopharma companies seeking more than just multiomics services; they want a collaborative partner to uncover deeper insights into disease biology,” stated Dr. Olale. “Jennifer and I are excited to lead this next growth phase, utilizing our comprehensive multiomic platform to drive advancements in personalized medicine, drug discovery, and the treatment of genetic diseases. Our aim is to integrate these technologies with AI and machine learning to deliver precision medicine solutions that will transform healthcare.”
Headquartered in Foster City, California, MedGenome U.S. provides a wide array of multiomic services that encompass genomics, epigenomics, transcriptomics, and proteomics. The company’s team of expert scientists and bioinformaticians collaborates with clients to tackle the complex challenges associated with rare diseases, oncology, and genetic disorders.
Jennifer Rose, MedGenome’s Chief Commercial Officer, emphasized the significance of this moment in genomics, stating, “Genomics is emerging as a powerful driver for precision medicine. Our extensive global reach—especially in India, South Asia, Africa, and Latin America—combined with advanced capabilities in spatial transcriptomics, single-cell sequencing, long-read technologies, and genomics-driven antibody drug discovery, uniquely positions us to offer cutting-edge solutions for drug discovery, novel diagnostics, and personalized therapies. We are dedicated to partnering with biopharma to leverage these transformative technologies, ultimately revolutionizing patient care and enhancing outcomes for millions worldwide.”
Dr. Olale’s move to CEO comes after his previous tenure as Chairman of MedGenome’s Board of Directors, where he played a crucial role in shaping the company’s strategic direction. He succeeds Dr. Amit Kakar, Managing Partner and Head of Novo Holdings Asia, who now serves as Chairman.
“With Felix at the helm of our North American operations and Dr. Vedam Ramprasad leading our business in India, we have a strong leadership team ready to accelerate MedGenome’s growth and expand its global impact,” remarked Mahesh Pratapneni, CEO of MedGenome.
Jennifer Rose brings a wealth of experience in life sciences, having previously held the position of Regional Vice President of Business Development at Precision for Medicine, along with senior roles at NeoGenomics Laboratories, GE Healthcare, PerkinElmer, and Thomson Reuters. She holds a Master’s degree in Chemical Engineering from the University of Connecticut and a Bachelor’s degree from Clemson University.
With this new leadership team in place, MedGenome U.S. is well-positioned to deepen partnerships with biopharma and academic researchers, expand its market presence, and deliver the next generation of multiomic technologies and end-to-end drug discovery support, paving the way for a transformative future in personalized medicine.
About MedGenome
MedGenome is a global leader in multiomics, genomics, and bioinformatics solutions, with a mission to leverage genetic data to advance precision medicine. Headquartered in Foster City, Calif., MedGenome collaborates with researchers and biopharma companies worldwide to provide deep insights into disease mechanisms, diagnostics, and therapeutic strategies. With expertise in rare diseases, oncology, and genetic disorders, MedGenome’s comprehensive multiomic platform integrates long-read sequencing, spatial multiomics, single-cell analysis, AI-driven insights and genomics-driven antibody discovery capabilities, to transform discoveries in healthcare and improve patient care.
